Somewhat Positive Press Coverage Somewhat Likely to Impact Concert Pharmaceuticals (CNCE) Share Price

Media headlines about Concert Pharmaceuticals (NASDAQ:CNCE) have been trending somewhat positive on Friday, Alpha One reports. Alpha One, a subsidiary of Accern, scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a news sentiment score of 0.13 on Alpha One’s scale. Alpha One also assigned news headlines about the biotechnology company an impact score of 50 out of 100, indicating that recent press coverage is somewhat likely to have an impact on the company’s share price in the next few days.

Insider Buying and Selling by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (CNCE) traded down 0.08% during trading on Friday, hitting $13.28. 172,416 shares of the stock traded hands. The company’s 50 day moving average price is $14.19 and its 200 day moving average price is $12.61. Concert Pharmaceuticals has a 12 month low of $7.11 and a 12 month high of $19.11. The company’s market cap is $299.62 million.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.06. The business had revenue of $0.02 million for the quarter. Concert Pharmaceuticals had a negative return on equity of 55.30% and a negative net margin of 36,357.25%. On average, equities research analysts anticipate that Concert Pharmaceuticals will post ($2.70) EPS for the current fiscal year.

Several equities analysts have recently issued reports on CNCE shares. Aegis restated a “buy” rating and set a $25.00 price objective on shares of Concert Pharmaceuticals in a report on Wednesday, April 5th. Zacks Investment Research upgraded shares of Concert Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Thursday, March 9th. Finally, Stifel Nicolaus restated a “buy” rating and set a $31.00 price objective on shares of Concert Pharmaceuticals in a report on Wednesday, April 5th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $26.40.

WARNING: This article was first reported by sleekmoney and is the property of of sleekmoney. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *